138 related articles for article (PubMed ID: 19466290)
1. Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors.
Jablonka F; Schindler F; Lajolo PP; Pinczowski H; Fonseca FL; Barbieri A; Massonetto LH; Katto FT; Del Giglio A
Sao Paulo Med J; 2009 Jan; 127(1):19-22. PubMed ID: 19466290
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
3. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
4. Markers of bone metastases in breast and lung cancers.
Bilgin E; Yasasever V; Soydinc HO; Yasasever CT; Ozturk N; Duranyildiz D
Asian Pac J Cancer Prev; 2012; 13(9):4331-4. PubMed ID: 23167338
[TBL] [Abstract][Full Text] [Related]
5. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.
Ali SM; Demers LM; Leitzel K; Harvey HA; Clemens D; Mallinak N; Engle L; Chinchilli V; Costa L; Brady C; Seaman J; Lipton A
Ann Oncol; 2004 Mar; 15(3):455-9. PubMed ID: 14998848
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
[TBL] [Abstract][Full Text] [Related]
7. Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis.
Zhang Y; Yi M; Cao J; Hou C; Zhou Y; Zhong Y
J Int Med Res; 2016 Apr; 44(2):192-200. PubMed ID: 26857861
[TBL] [Abstract][Full Text] [Related]
8. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
Morris PG; Fazio M; Farooki A; Estilo C; Mallam D; Conlin A; Patil S; Fleisher M; Cremers S; Huryn J; Hudis CA; Fornier MN
J Oral Maxillofac Surg; 2012 Dec; 70(12):2768-75. PubMed ID: 22330331
[TBL] [Abstract][Full Text] [Related]
9. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
10. Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.
Zafeirakis A; Papatheodorou G; Arhontakis A; Gouliamos A; Vlahos L; Limouris GS
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):103-13. PubMed ID: 19662405
[TBL] [Abstract][Full Text] [Related]
11. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.
Ulrich U; Rhiem K; Schmolling J; Flaskamp C; Paffenholz I; Sälzer H; Bauknecht T; Schlebusch H
Arch Gynecol Obstet; 2001 Jan; 264(4):186-90. PubMed ID: 11205705
[TBL] [Abstract][Full Text] [Related]
12. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
[TBL] [Abstract][Full Text] [Related]
14. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
15. Serum Levels of NTx and TRACP5b in Giant Cell Tumor of Bone and its Clinical Implications.
Chen J; Younusi A; Cao L; Xu L; Zhou Y; Zhen T; Song X
Clin Lab; 2015; 61(8):1077-81. PubMed ID: 26427154
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
17. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers].
Yamamoto I; Morita R; Konishi J; Shigeno C; Ikekubo K; Hino M; Sone T; Fujimoto R
Kaku Igaku; 1995 May; 32(5):501-10. PubMed ID: 7596071
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Sasada S; Okamoto N; Morishita N; Shiroyama T; Otsuka T; Miyamoto N; Taira K; Daga H; Takeda K; Hirashima T
Anticancer Res; 2015 Jul; 35(7):3987-93. PubMed ID: 26124346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]